CN106975045A - A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof - Google Patents
A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof Download PDFInfo
- Publication number
- CN106975045A CN106975045A CN201610023855.5A CN201610023855A CN106975045A CN 106975045 A CN106975045 A CN 106975045A CN 201610023855 A CN201610023855 A CN 201610023855A CN 106975045 A CN106975045 A CN 106975045A
- Authority
- CN
- China
- Prior art keywords
- solution
- parts
- antiviral
- preparation
- neulized inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 42
- 239000003186 pharmaceutical solution Substances 0.000 title claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 239000000341 volatile oil Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 244000001632 Acorus gramineus Species 0.000 claims description 4
- 235000013073 Acorus gramineus Nutrition 0.000 claims description 4
- 244000163122 Curcuma domestica Species 0.000 claims description 4
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 4
- 241000576429 Forsythia suspensa Species 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 235000014676 Phragmites communis Nutrition 0.000 claims description 4
- 240000002505 Pogostemon cablin Species 0.000 claims description 4
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 4
- 241000405414 Rehmannia Species 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000010231 banlangen Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000003373 curcuma longa Nutrition 0.000 claims description 4
- 239000010440 gypsum Substances 0.000 claims description 4
- 229910052602 gypsum Inorganic materials 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000013976 turmeric Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- -1 citrate-phosphate disodium hydrogen Chemical class 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- BUCIWTBCUUHRHZ-UHFFFAOYSA-K potassium;disodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O BUCIWTBCUUHRHZ-UHFFFAOYSA-K 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- IGHGOYDCVRUTSU-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O IGHGOYDCVRUTSU-UHFFFAOYSA-M 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 239000008215 water for injection Substances 0.000 description 51
- 238000003756 stirring Methods 0.000 description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 229940041682 inhalant solution Drugs 0.000 description 18
- 238000007789 sealing Methods 0.000 description 13
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 11
- 238000005660 chlorination reaction Methods 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of antiviral Neulized inhalation pharmaceutical solutions, belong to galenic pharmacy field.A kind of antiviral Neulized inhalation pharmaceutical solutions, including (1) antiviral active ingredient；(2) isotonic agent and solvent, can also include buffer solution.Pharmaceutical solutions prepared by the present invention compensate for the blank on domestic market, can prevent due to a lack of the special preparation medicine of Inhalation in Treating.Convenient using process and pharmaceutical solutions prepared by the present invention is to aim at Neulized inhalation to be designed with patient, is supported the use with atomizer, compared with antiviral oral liquor, method of administration is different, and dosage is reduced, and security is improved.
Description
Technical field
The present invention relates to a kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof, belong to galenic pharmacy neck
Domain.
Background technology
Influenza (abbreviation influenza) is ARI caused by influenza virus, is also a kind of biography
The disease that metachromia is strong, spread speed is fast.Its spittle main through the air, interpersonal contact or
With the contact transmission of contaminated article.Typically clinical symptoms are：It is anxious play hyperpyrexia, it is overall pain, significantly weary
Power and slight respiratory symptom.General autumn and winter is its high-incidence season, caused complication and the phenomena of mortality
It is very serious.
Antiviral oral liquor clearing heat and expelling damp, removing pattogenic heat from the blood and toxic material from the body, for anemopyretic cold, influenza.Antiviral oral liquor
Not only have obvious action to the prevention, treatment and control of regional influenza, and to caused by virus other
Disease has significant curative effect.But be administered orally and work slowly, consumption is big, and toxic side effect is larger, therefore urgently opens
The formulation that to send out a kind of safer, allows medicament to be directly entered respiratory tract, dosage is small, rapid-action, reduces
Adverse reaction, improves clinical application safety.
The content of the invention
The present invention solves the technical problem of provide it is a kind of safely, effectively, the antiviral mist of good quality
Change suction pharmaceutical solutions；Present invention also offers the preparation method of said preparation.
The present invention is achieved by the following technical solutions：
A kind of antiviral Neulized inhalation pharmaceutical solutions, including：
(1) antiviral active ingredient；
(2) isotonic agent and solvent；
Buffer solution can also be added.
Wherein, the mass ratio of active ingredient and isotonic agent is 1: 1-1: 5.
The composition (by weight) of active ingredient：
10-15 parts of Radix Isatidis, 3-6 parts of the capsule of weeping forsythia, 4-8 parts of gypsum, 1.5-4.5 parts of the wind-weed, glutinous rehmannia 2-5
Part, 1.5-4.5 parts of grass-leaved sweetflag, 1.5-4.5 parts of root tuber of aromatic turmeric, 1.6-4.8 parts of Pogostemon cablin, 4-8 parts of reed rhizome；
Preferably (by weight)：
12.87 parts of Radix Isatidis, 4.65 parts of the capsule of weeping forsythia, 5.72 parts of gypsum, 2.5 parts of the wind-weed, 3.22 parts of glutinous rehmannia,
2.50 parts of grass-leaved sweetflag, 2.50 parts of root tuber of aromatic turmeric, 2.86 parts of Pogostemon cablin, 6.08 parts of reed rhizome；
The preparation method of active ingredient is：
Nine taste medicines are weighed according to above-mentioned parts by weight, secondary, 3 hours first times is added water to cook, collects volatile oil,
Included with HYDROXYPROPYL BETA-CYCLODEXTRIN, or 1.5 hours for the first time, while collecting volatile oil and volatile oil milkiness
Liquid；Second 20 minutes 1 hour, filtration, filtrate merged, be concentrated into it is appropriate, plus 85% more than ethanol
It is 70% to make alcohol content, is stood, and filtration, filtrate recycling ethanol is simultaneously concentrated into thick paste, adds volatile oil clathrate compound
Or volatile oil, volatile oil emulsion are added, obtain the active ingredient of the present invention；
Above volatile oil, volatile oil emulsion also can use solubilizer (such as：Tween 80) dissolving after add thick paste
In.
Isotonic agent is in sodium chloride, potassium chloride, magnesium chloride, calcium chloride, glucose, xylitol, sorbierite
One kind.
Buffer solution be citric acid-sodium citrate, citrate-phosphate disodium hydrogen, potassium dihydrogen phosphate-disodium hydrogen phosphate,
One kind in citric acid-sodium hydroxide, citric acid-disodium hydrogen phosphate.
Appropriate flavouring can also be added in the present invention.
The pH value of aerosol inhalation solution is 3.0-8.5；Preferable ph is 4.0-7.0.
The consumption of aerosol inhalation solution is 0.01-1.0 times of antiviral oral liquor consumption；Preferable amount is disease-resistant
0.05-0.8 times of malicious oral liquid consumption；More preferably consumption is 0.1-0.5 times of antiviral oral liquor consumption.
Antiviral Neulized inhalation pharmaceutical solutions of the present invention can be used for treatment anemopyretic cold, influenza etc..
It is an advantage of the present invention to provide a kind of novel form better than antiviral oral liquor, said preparation is directly by exhaling
Road suction is inhaled, in localized clusters into higher concentration, and the receptor or target acceptor of airway surface is directly acted on
And play a role, and can directly be absorbed from air flue mucous membrane and lung, the administering mode can be straight by effective component
Connect and be delivered to focus, safely and effectively, bioavilability is high, can realize low dosage and fast and effectively treat,
Thus have a clear superiority.
Pharmaceutical solutions prepared by the present invention compensate for the blank on domestic market, can prevent due to a lack of suction
Enter to treat special preparation medicine.And pharmaceutical solutions prepared by the present invention is to aim at Neulized inhalation to be set with patient
Meter, is supported the use with atomizer, convenient using process, compared with antiviral oral liquor, and method of administration is different,
Dosage is reduced, and security is improved.
Beneficial effects of the present invention are further illustrated below by way of test example：
Prepare influenza rat model 80, be randomly divided into Normal group, positive controls, medicine group one,
Medicine group two, medicine group three, medicine group four, medicine group five, medicine group six, every group 10, wherein, just
Normal control group gives normal saline gavage；Positive controls give antiviral oral liquor gavage；Medicine group
First, two, three, four, five, six antiviral aerosol inhalation solution is given respectively (consumption is respectively antiviral mouth
Take 0.01 times, 0.05 times, 0.1 times, 0.5 times, 0.8 times, 1.0 times of liquid), successive administration 3 days,
Observation after treatment, after the cure rate of each group, adverse reaction rate, and last dose lung tissue and
Peak concentration of drug in blood.Specifically it see the table below：
Situation after the treatment of table each group
It can thus be seen that each medicine group has preferable therapeutic action to influenza rat, wherein medicine group
Therapeutic effect is substantially better than positive controls, and does not have adverse reaction.
In summary, medicine group dosage is small, and adverse reaction is few, and medicine it is main lung be gathered into compared with
High concentration, is conducive to effective component to directly act on focus, and bioavilability is high, realizes low dosage and fast
Fast effective treatment, thus have a clear superiority.
Equally, the effect of medicine group treatment anemopyretic cold is also significantly better than antiviral oral liquor.
The therapeutic effect of the antiviral aerosol inhalation solution of the present invention is substantially better than antiviral oral liquor, has filled up mesh
The blank of antiviral special aerosol inhalation solution on preceding domestic market, compared with antiviral oral liquor, is used
Dosage greatly reduces, and is 0.01-1.0 times of antiviral oral liquor, preferably 0.05-0.8 times, more preferably
For 0.1-0.5 times, while changing method of administration, the generation of adverse reaction is reduced, therefore, present invention tool
It is standby creative with prominent substantive distinguishing features and significantly progressive.
Embodiment
The consumption of material used in material used in the production process and preparation of following pharmaceutical preparation embodiment or preparation is not
It is limited to character express, the formulation method of all pharmaceutical compositions provided containing the present invention belongs to the present invention's
Protection domain.
Embodiment 1
(1) preparation of active ingredient：
12.87 parts of Radix Isatidis, 4.65 parts of the capsule of weeping forsythia, 5.72 parts of gypsum, 2.5 parts of the wind-weed, 3.22 parts of glutinous rehmannia,
2.50 parts of grass-leaved sweetflag, 2.50 parts of root tuber of aromatic turmeric, 2.86 parts of Pogostemon cablin, 6.08 parts of reed rhizome
Nine taste medicines are weighed according to above-mentioned parts by weight, secondary, 3 hours first times is added water to cook, collects volatile oil,
Included with HYDROXYPROPYL BETA-CYCLODEXTRIN, or 1.5 hours for the first time, while collecting volatile oil and volatile oil milkiness
Liquid；Second 20 minutes 1 hour, filtration, filtrate merged, be concentrated into it is appropriate, plus 85% more than ethanol
It is 70% to make alcohol content, is stood, filtration, and filtrate recycling ethanol is simultaneously concentrated into appropriate, addition volatile oil clathrate compound
Or volatile oil, volatile oil emulsion are added, obtain the active ingredient of the present invention；
Above volatile oil, volatile oil emulsion also can use solubilizer (such as：Tween 80) dissolving after add thick paste
In.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.4mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 5.0-7.0, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 2
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium, adds appropriate water for injection, is stirred to dissolve, obtains solution 2；Solution 1 and solution is 2-in-1 simultaneously, stirring
Uniformly, solution 3 is obtained；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to the molten of 0.4mol/L in right amount
Liquid, stirring is slowly added into solution 3, regulation pH value to 4.0-7.0, plus water for injection 1000ml, is filled
Dress, sealing, are produced.
Embodiment 3
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Magnesium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.2mo1/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 4.0-6.0, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 4
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Calcium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.4mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 5.0-6.5, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 5
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take sodium citrate appropriate, plus water for injection is configured to 0.4mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 6.0-7.0, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 6
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take grape
Sugar and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.4mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 4.5-5.5, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 7
(1) preparation of active ingredient：Be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take xylose
Alcohol and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take Sodium hydroxide q. s, plus appropriate water for injection to be configured to 0.1mo1/L
Solution, stirring be slowly added into solution 3, regulation pH value to 3.0-5.0, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 8
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium and potassium dihydrogen phosphate, add appropriate water for injection, are stirred to dissolve, obtain solution 2；By solution 1 and solution
It is 2-in-1 simultaneously to stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured in right amount
0.4mol/L solution, stirring is slowly added into solution 3, regulation pH value to 7.5-8.5, plus injection
Water 1000ml, filling, sealing is produced.
Embodiment 9
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take sorb
Alcohol and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.2mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 5.0-6.0, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 10
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.2mol/L in right amount
Solution, stirring be slowly added into solution 3, regulation pH value to 5.0-6.5, plus water for injection 1000ml,
Filling, sealing, is produced.
Embodiment 11
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Magnesium, adds appropriate water for injection, is stirred to dissolve, obtains solution 2；Solution 1 and solution is 2-in-1 simultaneously, stirring
Uniformly, solution 3 is obtained；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to the molten of 0.4mol/L in right amount
Liquid, stirring is slowly added into solution 3, regulation pH value to 6.5-8.5, plus water for injection 1000ml, is filled
Dress, sealing, are produced.
Embodiment 12
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium, adds appropriate water for injection, is stirred to dissolve, obtains solution 2；Solution 1 and solution is 2-in-1 simultaneously, stirring
Uniformly, solution 3 is obtained；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to the molten of 0.4mol/L in right amount
Liquid, adds Aspartame in right amount, stirs, be slowly added into solution 3, adjusts pH value to 4.0-7.0,
Plus water for injection 1000ml, filling, sealing, produce.
Embodiment 13
(1) preparation of active ingredient：Preparation method be the same as Example 1.
(2) preparation of antiviral Neulized inhalation solution：
Active ingredient is weighed by recipe quantity, appropriate water for injection is added, stirs, obtain solution 1；Take chlorination
Sodium and citric acid, add appropriate water for injection, are stirred to dissolve, obtain solution 2；Solution 1 and solution is 2-in-1
And, stir, obtain solution 3；It is another to take disodium hydrogen phosphate appropriate, plus water for injection is configured to 0.4mol/L in right amount
Solution, it is appropriate to add flavouring, stirs, is slowly added into solution 3, regulation pH value to 4.0-7.0,
Plus water for injection 1000ml, filling, sealing, produce.
Claims (10)
1. a kind of antiviral Neulized inhalation pharmaceutical solutions, it is characterised in that antiviral effectively including (1)
Composition；(2) isotonic agent and solvent；
Wherein, the mass ratio of active ingredient and isotonic agent is 1: 1-1: 5.
2. preparation according to claim 1, it is characterised in that active ingredient is prepared obtaining：
12.87 parts of Radix Isatidis, 4.65 parts of the capsule of weeping forsythia, 5.72 parts of gypsum, 2.5 parts of the wind-weed, 3.22 parts of glutinous rehmannia,
2.50 parts of grass-leaved sweetflag, 2.50 parts of root tuber of aromatic turmeric, 2.86 parts of Pogostemon cablin, 6.08 parts of reed rhizome
Nine taste medicines are weighed according to above-mentioned parts by weight, secondary, 3 hours first times is added water to cook, collects volatile oil,
Included with HYDROXYPROPYL BETA-CYCLODEXTRIN, or 1.5 hours for the first time, while collecting volatile oil and volatile oil milkiness
Liquid；Second 20 minutes 1 hour, filtration, filtrate merged, be concentrated into it is appropriate, plus 85% more than ethanol
It is 70% to make alcohol content, is stood, filtration, and filtrate recycling ethanol is simultaneously concentrated into appropriate, addition volatile oil clathrate compound
Or volatile oil, volatile oil emulsion are added, obtain the active ingredient of the present invention.
3. preparation according to claim 1, it is characterised in that described isotonic agent is sodium chloride, chlorine
Change one kind in potassium, magnesium chloride, calcium chloride, glucose, xylitol, sorbierite.
4. preparation according to claim 1, it is characterised in that also include buffer solution in said preparation.
5. preparation according to claim 4, it is characterised in that described buffer solution is citric acid-lemon
Lemon acid sodium, citrate-phosphate disodium hydrogen, potassium dihydrogen phosphate-disodium hydrogen phosphate, citric acid-sodium hydroxide, Chinese holly
One kind in rafter acid-disodium hydrogen phosphate.
6. preparation according to claim 1, it is characterised in that Neulized inhalation is with the pH value of solution
3.0-8.5。
7. preparation according to claim 7, it is characterised in that Neulized inhalation is with the pH value of solution
4.0-7.0。
8. preparation according to claim 1, it is characterised in that Neulized inhalation is anti-with the consumption of solution
0.01-1.0 times of viral oral liquid consumption.
9. preparation according to claim 8, it is characterised in that Neulized inhalation is anti-with the consumption of solution
0.05-0.8 times of viral oral liquid consumption.
10. preparation according to claim 9, it is characterised in that Neulized inhalation is with the consumption of solution
0.1-0.5 times of antiviral oral liquor consumption.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110616959.8A CN113368208A (en) | 2016-01-15 | 2016-01-15 | Antiviral aerosol inhalation solution preparation and preparation method thereof |
| CN201610023855.5A CN106975045A (en) | 2016-01-15 | 2016-01-15 | A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023855.5A CN106975045A (en) | 2016-01-15 | 2016-01-15 | A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110616959.8A Division CN113368208A (en) | 2016-01-15 | 2016-01-15 | Antiviral aerosol inhalation solution preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106975045A true CN106975045A (en) | 2017-07-25 |
Family
ID=59340041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610023855.5A Pending CN106975045A (en) | 2016-01-15 | 2016-01-15 | A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof |
| CN202110616959.8A Pending CN113368208A (en) | 2016-01-15 | 2016-01-15 | Antiviral aerosol inhalation solution preparation and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110616959.8A Pending CN113368208A (en) | 2016-01-15 | 2016-01-15 | Antiviral aerosol inhalation solution preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106975045A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771398A (en) * | 2019-02-25 | 2019-05-21 | 广州南鑫药业有限公司 | A kind of Peramivir solution-type inhalant and preparation method thereof |
| CN110327313A (en) * | 2019-06-21 | 2019-10-15 | 中山大学 | A kind of naringenin aerosol inhalation solution preparation and preparation method thereof |
| CN110954645A (en) * | 2019-09-09 | 2020-04-03 | 山东琪康生物技术有限公司 | Detection method of high-quality Sihuang dysentery stopping granules |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101606903A (en) * | 2008-06-19 | 2009-12-23 | 北京韩美药品有限公司 | A kind of atomizing of ambroxol sucks with solution and preparation method thereof |
| CN102764405A (en) * | 2011-04-30 | 2012-11-07 | 顾建光 | Preparation method of antiviral oral liquid |
| CN102940856A (en) * | 2012-12-12 | 2013-02-27 | 杭州老桐君制药有限公司 | Method for preparing anti-viral oral liquid and product thereof |
-
2016
- 2016-01-15 CN CN201610023855.5A patent/CN106975045A/en active Pending
- 2016-01-15 CN CN202110616959.8A patent/CN113368208A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101606903A (en) * | 2008-06-19 | 2009-12-23 | 北京韩美药品有限公司 | A kind of atomizing of ambroxol sucks with solution and preparation method thereof |
| CN102764405A (en) * | 2011-04-30 | 2012-11-07 | 顾建光 | Preparation method of antiviral oral liquid |
| CN102940856A (en) * | 2012-12-12 | 2013-02-27 | 杭州老桐君制药有限公司 | Method for preparing anti-viral oral liquid and product thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771398A (en) * | 2019-02-25 | 2019-05-21 | 广州南鑫药业有限公司 | A kind of Peramivir solution-type inhalant and preparation method thereof |
| CN110327313A (en) * | 2019-06-21 | 2019-10-15 | 中山大学 | A kind of naringenin aerosol inhalation solution preparation and preparation method thereof |
| CN110954645A (en) * | 2019-09-09 | 2020-04-03 | 山东琪康生物技术有限公司 | Detection method of high-quality Sihuang dysentery stopping granules |
| CN110954645B (en) * | 2019-09-09 | 2020-09-29 | 山东琪康生物技术有限公司 | Detection method of high-quality Sihuang dysentery stopping granules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113368208A (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106974898A (en) | A kind of anxious branch Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN106975045A (en) | A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN106806359A (en) | A kind of Neulized inhalation pharmaceutical solutions of andrographolide or its pharmaceutical salts and preparation method thereof | |
| CN106806358A (en) | One seed ginseng wheat Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107789556A (en) | A kind of Juhong Tanke Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107184792A (en) | It is a kind of to treat Neulized inhalation pharmaceutical solutions of children's dyspneic cough and preparation method thereof | |
| CN107137518A (en) | A kind of 'Zhichuanling Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107137483A (en) | One kind, which is breathed heavily, can control Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107137502A (en) | A kind of cordate houttuynia Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN106806418A (en) | A kind of swap buffers Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107334754A (en) | A kind of Qing kailing Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN102008539B (en) | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN102258504A (en) | Compound salbutamol sulfate and ambroxol hydrochloride inhalation solution | |
| JPS61194031A (en) | Agent for promoting carcinostatic activity | |
| CN107773581A (en) | A kind of silver yellow Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107773593A (en) | A kind of infantile heat-clearing and antitussive Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN109966324A (en) | A kind of ginkgo biloba p.e Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107184518A (en) | A kind of toothpaste alleviated or mitigate acute/chronic pharyngitis and preparation method thereof | |
| CN104055921B (en) | A kind of pharmaceutical composition and application thereof for the treatment of oral lichen planus | |
| CN1954854A (en) | Traditional Chinese medicinal compound preparation for treating asthma and its preparation method | |
| CN107773588A (en) | A kind of trollflower Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN107137469A (en) | A kind of Shenfu Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN106138687A (en) | A kind of Chinese medicine composition preventing and treating the kidney deficiency type asthma | |
| CN104127533A (en) | Compound bronchitis syrup and preparation method | |
| JPS6233125A (en) | Carcinostatic action enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Applicant after: Beijing Kerui pharmaceutical Limited by Share Ltd profit innovation Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Applicant before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180906 Address after: 519031 Commercial Service Center of Guangdong-Australia Cooperative Science and Technology Industrial Park, 2522 Huandao North Road, Hengqin New District, Zhuhai City, Guangdong Province - 19 (Centralized Office Area) Applicant after: Ying Kerui (Hengqin) Pharmaceutical Research Institute Co Ltd Address before: 102299 Beijing 6 Changping District science and Technology Park No. 79, No. 24, No. Applicant before: Beijing Kerui pharmaceutical Limited by Share Ltd profit innovation |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170725 |